CureVac, the German pharma company said on Tuesday (July 6) that it was suing BioNTech, its rival in pharma sector for patent infringement. The lawsuit of patent infringement is for them mRNA technology to develop Comirnaty coronvirus vaccine.

CureVac sues BioNTech over Covid vaccine technology

German biotech company CureVac said on Wednesday its COVID-19 vaccine was only 48 per cent effective in the final trial, missing the study's main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union.

Germany's COVID-19 vaccine CureVac disappoints in pivotal final trial, with only 48 per cent efficacy

Britain has agreed on a deal with German biotech firm CureVac to work to develop vaccines against coronavirus variants. The country has even, to this end, placed an initial order for 50 million doses in case they are needed.

UK plans to work with Germany's CureVac on vaccines against coronavirus variants

German pharmaceutical firms Bayer and CureVac said Thursday that they have joined forces in the development of CureVac's Covid-19 vaccine candidate. Under the deal, CureVac will be able to tap Bayer's expertise and established infrastructure, according to a joint statement.

Bayer, CureVac to 'join forces' on Covid-19 vaccine candidate

Unlisted biotech firm CureVac on Wednesday become the second company after rival BioNTech to launch human trials of an experimental coronavirus vaccine in Germany, eyeing potential regulatory approval in mid-2021.

German biotech firm starts human trials of experimental COVID-19 vaccine | WION-DW Partnership

As the world comes to grips with the coronavirus pandemic the country's invest money and resources to push for a vaccine. Germany has taken a 23% stake in a private company and the company is called CureVac. Watch report.

Global race for Coronavirus vaccine: Germany buys 23% stake in CureVac

curevac

Curevac, News on Curevac, stories on Curevac, articles on Curevac, Curevac stories at Wion, Curevac news, Curevac latest news